Abstract | AIM: METHODS: RESULTS: The mean HFC of the high dose HL group, but not of the low dose group, declined significantly after 12 wk of treatment (high dose vs placebo, P = 0.033; low dose vs placebo, P = 0.386). The mean changes of HFC from baseline at week 12 were -1.7% ± 3.1% in the high dose group (P = 0.018), -1.21% ± 4.97% in the low dose group (P = 0.254) and 0.61% ± 3.87% in the placebo group (relative changes compared to baseline, high dose were: -12.1% ± 23.5%, low dose: -3.2% ± 32.0%, and placebo: 7.6% ± 44.0%). Serum ALT levels also tended to decrease in the groups receiving HL tablet while other factors were unaffected. There were no moderate or severe treatment-related safety issues during the study. CONCLUSION: HL tablet is effective in reducing HFC without any negative lipid profiles, BMI changes and adverse effects.
|
Authors | Jae Yoon Jeong, Joo Hyun Sohn, Yang Hyun Baek, Yong Kyun Cho, Yongsoo Kim, Hyeonjin Kim |
Journal | World journal of gastroenterology
(World J Gastroenterol)
Vol. 23
Issue 32
Pg. 5977-5985
(Aug 28 2017)
ISSN: 2219-2840 [Electronic] United States |
PMID | 28932090
(Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Lipids
- Placebos
- Plant Extracts
- Tablets
|
Topics |
- Adult
- Body Mass Index
- Female
- Humans
- Lipids
(blood)
- Liver
(diagnostic imaging, drug effects, pathology)
- Liver Function Tests
- Magnetic Resonance Spectroscopy
- Magnolia
(chemistry)
- Male
- Middle Aged
- Non-alcoholic Fatty Liver Disease
(blood, diagnostic imaging, drug therapy, pathology)
- Placebos
- Plant Extracts
(pharmacology, therapeutic use)
- Tablets
- Treatment Outcome
- Ultrasonography
|